Literature DB >> 18774954

High-dose therapy and autologous stem cell transplantation for follicular lymphoma undergoing transformation to diffuse large B-cell lymphoma.

Mehdi Hamadani1, Don M Benson, Thomas S Lin, Pierluigi Porcu, Kristie A Blum, Steven M Devine.   

Abstract

The transformation of follicular lymphoma (FL) to high-grade histology occurs in up to 70% of patients. The role of hematopoietic stem cell transplantation (HSCT) in transformed FL is poorly defined. Twenty-four FL patients with histologically confirmed transformation to diffuse large B-cell lymphoma underwent unpurged autologous HSCT at our institution. Their median age was 56 yr. The median number of prior chemotherapies was 2 (range 1-6). Thirteen patients had residual nodal disease measuring more than 2 cm and four patients had bulky disease at the time of HSCT. Six patients had refractory disease at transplantation. At a median follow-up of 38 months, 3-yr progression-free survival following autologous HSCT was 40%. The 3-yr overall survival was 52%. The cumulative incidence of relapse and non-relapse mortality rate was 41% and 25%, respectively.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18774954     DOI: 10.1111/j.1600-0609.2008.01146.x

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  7 in total

Review 1.  Treatment options for transformed lymphoma: incorporating allogeneic stem cell transplantation in a multimodality approach.

Authors:  Nishitha Reddy; Bipin N Savani
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-11       Impact factor: 5.742

2.  Conditioning with treosulfan and fludarabine for patients with refractory or relapsed non-Hodgkin lymphoma.

Authors:  Michael Schmitt; Rudolf Trenschel; Herbert G Sayer; Catarina Schneider; Aenne Glass; Inken Hilgendorf; Anne Treschl; Christian Junghanss; Kersten Borchert; Michael Koenigsmann; Jochen Casper; Dietrich W Beelen; Mathias Freund; Christoph Kahl
Journal:  Mol Clin Oncol       Date:  2014-06-02

Review 3.  Transformation in follicular lymphoma: biology, prognosis, and therapeutic options.

Authors:  Eric Wong; Michael Dickinson
Journal:  Curr Oncol Rep       Date:  2012-10       Impact factor: 5.075

4.  Allogeneic stem cell transplantation for patients with relapsed chemorefractory aggressive non-hodgkin lymphomas.

Authors:  Mehdi Hamadani; Don M Benson; Craig C Hofmeister; Patrick Elder; William Blum; Pierluigi Porcu; Ramiro Garzon; Kristie A Blum; Thomas S Lin; Guido Marcucci; Steven M Devine
Journal:  Biol Blood Marrow Transplant       Date:  2009-03-09       Impact factor: 5.742

5.  Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma.

Authors:  Baldeep Wirk; Timothy S Fenske; Mehdi Hamadani; Mei-Jie Zhang; Zhen-Huan Hu; Görgün Akpek; Mahmoud D Aljurf; Philippe Armand; Ernesto Ayala; Veronika Bachanova; Brian Bolwell; Mitchell S Cairo; Amanda Cashen; Yi-Bin Chen; Luciano J Costa; Shatha Farhan; César O Freytes; James L Gajewski; John Gibson; Gregory A Hale; Leona A Holmberg; Jack W Hsu; David J Inwards; Rummurti T Kamble; Dipnarine Maharaj; Richard T Maziarz; Reinhold Munker; Rajneesh Nath; Nishitha M Reddy; Craig B Reeder; David A Rizzieri; Craig S Sauter; Bipin N Savani; Harry C Schouten; Anna Sureda; Julie M Vose; Edmund K Waller; Peter H Wiernik; Robert Peter Gale; Linda J Burns; Wael Saber
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-15       Impact factor: 5.742

6.  Controversies and recent advances in hematopoietic cell transplantation for follicular non-hodgkin lymphoma.

Authors:  Abraham S Kanate; Mohamed A Kharfan-Dabaja; Mehdi Hamadani
Journal:  Bone Marrow Res       Date:  2012-10-11

7.  The role of local radiotherapy following rituximab-containing chemotherapy in patients with transformed indolent B-cell lymphoma.

Authors:  Kenji Nozaki; Dai Maruyama; Akiko Miyagi Maeshima; Kinuko Tajima; Jun Itami; Takafumi Shichijo; Sayako Yuda; Tomotaka Suzuki; Kosuke Toyoda; Nobuhiko Yamauchi; Shinichi Makita; Suguru Fukuhara; Wataru Munakata; Yukio Kobayashi; Hirokazu Taniguchi; Koji Izutsu; Kensei Tobinai
Journal:  Eur J Haematol       Date:  2020-11-06       Impact factor: 2.997

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.